These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 21538343)

  • 1. Phase 1/2 study of everolimus in advanced hepatocellular carcinoma.
    Zhu AX; Abrams TA; Miksad R; Blaszkowsky LS; Meyerhardt JA; Zheng H; Muzikansky A; Clark JW; Kwak EL; Schrag D; Jors KR; Fuchs CS; Iafrate AJ; Borger DR; Ryan DP
    Cancer; 2011 Nov; 117(22):5094-102. PubMed ID: 21538343
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I study investigating everolimus combined with sorafenib in patients with advanced hepatocellular carcinoma.
    Finn RS; Poon RT; Yau T; Klümpen HJ; Chen LT; Kang YK; Kim TY; Gomez-Martin C; Rodriguez-Lope C; Kunz T; Paquet T; Brandt U; Sellami D; Bruix J
    J Hepatol; 2013 Dec; 59(6):1271-7. PubMed ID: 23928403
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial.
    Zhu AX; Kudo M; Assenat E; Cattan S; Kang YK; Lim HY; Poon RT; Blanc JF; Vogel A; Chen CL; Dorval E; Peck-Radosavljevic M; Santoro A; Daniele B; Furuse J; Jappe A; Perraud K; Anak O; Sellami DB; Chen LT
    JAMA; 2014 Jul; 312(1):57-67. PubMed ID: 25058218
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic potential and adverse events of everolimus for treatment of hepatocellular carcinoma - systematic review and meta-analysis.
    Yamanaka K; Petrulionis M; Lin S; Gao C; Galli U; Richter S; Winkler S; Houben P; Schultze D; Hatano E; Schemmer P
    Cancer Med; 2013 Dec; 2(6):862-71. PubMed ID: 24403259
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II trial of erlotinib and docetaxel in advanced and refractory hepatocellular and biliary cancers: Hoosier Oncology Group GI06-101.
    Chiorean EG; Ramasubbaiah R; Yu M; Picus J; Bufill JA; Tong Y; Coleman N; Johnston EL; Currie C; Loehrer PJ
    Oncologist; 2012; 17(1):13. PubMed ID: 22210086
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A multicenter, phase II trial of everolimus in locally advanced or metastatic thyroid cancer of all histologic subtypes.
    Lim SM; Chang H; Yoon MJ; Hong YK; Kim H; Chung WY; Park CS; Nam KH; Kang SW; Kim MK; Kim SB; Lee SH; Kim HG; Na II; Kim YS; Choi MY; Kim JG; Park KU; Yun HJ; Kim JH; Cho BC
    Ann Oncol; 2013 Dec; 24(12):3089-94. PubMed ID: 24050953
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sorafenib with or without everolimus in patients with advanced hepatocellular carcinoma (HCC): a randomized multicenter, multinational phase II trial (SAKK 77/08 and SASL 29).
    Koeberle D; Dufour JF; Demeter G; Li Q; Ribi K; Samaras P; Saletti P; Roth AD; Horber D; Buehlmann M; Wagner AD; Montemurro M; Lakatos G; Feilchenfeldt J; Peck-Radosavljevic M; Rauch D; Tschanz B; Bodoky G;
    Ann Oncol; 2016 May; 27(5):856-61. PubMed ID: 26884590
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I/II study of temsirolimus for patients with unresectable Hepatocellular Carcinoma (HCC)- a correlative study to explore potential biomarkers for response.
    Yeo W; Chan SL; Mo FK; Chu CM; Hui JW; Tong JH; Chan AW; Koh J; Hui EP; Loong H; Lee K; Li L; Ma B; To KF; Yu SC
    BMC Cancer; 2015 May; 15():395. PubMed ID: 25962426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study of everolimus in metastatic urothelial cancer.
    Milowsky MI; Iyer G; Regazzi AM; Al-Ahmadie H; Gerst SR; Ostrovnaya I; Gellert LL; Kaplan R; Garcia-Grossman IR; Pendse D; Balar AV; Flaherty AM; Trout A; Solit DB; Bajorin DF
    BJU Int; 2013 Aug; 112(4):462-70. PubMed ID: 23551593
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Everolimus for advanced pancreatic neuroendocrine tumors.
    Yao JC; Shah MH; Ito T; Bohas CL; Wolin EM; Van Cutsem E; Hobday TJ; Okusaka T; Capdevila J; de Vries EG; Tomassetti P; Pavel ME; Hoosen S; Haas T; Lincy J; Lebwohl D; Öberg K;
    N Engl J Med; 2011 Feb; 364(6):514-23. PubMed ID: 21306238
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I trial of capecitabine plus everolimus (RAD001) in patients with previously treated metastatic gastric cancer.
    Lim T; Lee J; Lee DJ; Lee HY; Han B; Baek KK; Ahn HK; Lee SJ; Park SH; Park JO; Park YS; Lim HY; Kim KM; Kang WK
    Cancer Chemother Pharmacol; 2011 Jul; 68(1):255-62. PubMed ID: 21526353
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma.
    Slomovitz BM; Lu KH; Johnston T; Coleman RL; Munsell M; Broaddus RR; Walker C; Ramondetta LM; Burke TW; Gershenson DM; Wolf J
    Cancer; 2010 Dec; 116(23):5415-9. PubMed ID: 20681032
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multicenter phase II study of everolimus in patients with previously treated metastatic gastric cancer.
    Doi T; Muro K; Boku N; Yamada Y; Nishina T; Takiuchi H; Komatsu Y; Hamamoto Y; Ohno N; Fujita Y; Robson M; Ohtsu A
    J Clin Oncol; 2010 Apr; 28(11):1904-10. PubMed ID: 20231677
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomised clinical trial: comparison of two everolimus dosing schedules in patients with advanced hepatocellular carcinoma.
    Shiah HS; Chen CY; Dai CY; Hsiao CF; Lin YJ; Su WC; Chang JY; Whang-Peng J; Lin PW; Huang JD; Chen LT
    Aliment Pharmacol Ther; 2013 Jan; 37(1):62-73. PubMed ID: 23134470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer.
    Amato RJ; Jac J; Giessinger S; Saxena S; Willis JP
    Cancer; 2009 Jun; 115(11):2438-46. PubMed ID: 19306412
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activity and safety of RAD001 (everolimus) in patients affected by biliary tract cancer progressing after prior chemotherapy: a phase II ITMO study.
    Buzzoni R; Pusceddu S; Bajetta E; De Braud F; Platania M; Iannacone C; Cantore M; Mambrini A; Bertolini A; Alabiso O; Ciarlo A; Turco C; Mazzaferro V
    Ann Oncol; 2014 Aug; 25(8):1597-603. PubMed ID: 24827133
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Everolimus as second- or third-line treatment of advanced endometrial cancer: ENDORAD, a phase II trial of GINECO.
    Ray-Coquard I; Favier L; Weber B; Roemer-Becuwe C; Bougnoux P; Fabbro M; Floquet A; Joly F; Plantade A; Paraiso D; Pujade-Lauraine E
    Br J Cancer; 2013 May; 108(9):1771-7. PubMed ID: 23612453
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Everolimus and pasireotide for advanced and metastatic hepatocellular carcinoma.
    Sanoff HK; Kim R; Ivanova A; Alistar A; McRee AJ; O'Neil BH
    Invest New Drugs; 2015 Apr; 33(2):505-9. PubMed ID: 25613083
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma.
    Zhu AX; Stuart K; Blaszkowsky LS; Muzikansky A; Reitberg DP; Clark JW; Enzinger PC; Bhargava P; Meyerhardt JA; Horgan K; Fuchs CS; Ryan DP
    Cancer; 2007 Aug; 110(3):581-9. PubMed ID: 17583545
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multicenter phase II study of everolimus in patients with metastatic or recurrent bone and soft-tissue sarcomas after failure of anthracycline and ifosfamide.
    Yoo C; Lee J; Rha SY; Park KH; Kim TM; Kim YJ; Lee HJ; Lee KH; Ahn JH
    Invest New Drugs; 2013 Dec; 31(6):1602-8. PubMed ID: 24037083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.